{"id":12206,"date":"2025-05-14T15:03:00","date_gmt":"2025-05-14T15:03:00","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=12206"},"modified":"2025-05-14T15:03:00","modified_gmt":"2025-05-14T15:03:00","slug":"state-of-the-art-pmhc-stability-assessment","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/state-of-the-art-pmhc-stability-assessment\/","title":{"rendered":"State-of-the art pMHC stability assessment"},"content":{"rendered":"\n

Screen peptides or peptide libraries for optimal MHC binders. immunAware’s stability assay measures the dissociation of pMHC complexes in real-time at 37\u00b0C allowing you to discriminate between peptides that support the formation of stable (more likely to be immunogenic) or unstable (less likely to be immunogenic) peptide-MHC complexes.<\/h3>\n\n\n\n

The stability assay is ideally suited to further stratify peptide targets predicted to bind to MHC, whether to identify new vaccine targets or to screen protein drug candidates for harboring potential immunogenic fragments. More than 90 HLA allotypes can be assayed for pMHC stability.<\/p>\n\n\n\n

Assessment of peptide-MHC complex stability is an important parameter when screening for immunogenic peptides. The stability of any given peptide-MHC complex can be determined by monitoring the dissociation of immune complexes at 37\u00b0C and calculate the half-life. The half-life of a peptide-MHC complex have been demonstrated to be a better correlate of immunogenicity than the corresponding peptide affinity for the MHC (Harndahl et.al1<\/sup>).<\/p>\n\n\n\n

immunAware has developed a high-throughput assay to monitor the dissociation of peptide MHC class I complexes (figure below) and determine the half-life of any peptide. Their stability measurement service applies to all MHC class I molecules available and can assist your epitope \/ neo-epitope screening.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

The determination of the half-life of a set of peptides (pairwise matched for HLA-A*02:01 affinity) previously described as being either immunogenic or non-immunogenic (Assarsson E, et. al2<\/sup>) revealed that verified T cell epitopes produced significantly longer half-lives compared to verified non-immunogenic peptides. A ROC analysis of the half-lives in the two groups produced an AUC of 0.97 suggesting that stability is a key parameter for immunogenicity assessments.<\/p>\n\n\n\n


Bibliography<\/strong><\/p>\n\n\n\n

    \n
  1. Harndahl, M., M. Rasmussen, G. Roder, I. Dalgaard Pedersen, M. Sorensen, M. Nielsen and S. Buus (2012). \u201cPeptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity.\u201d Eur J Immunol 42(6): 1405-1416.<\/li>\n\n\n\n
  2. Assarsson E1, Sidney J, Oseroff C, Pasquetto V, Bui HH, Frahm N, Brander C, Peters B, Grey H, Sette A. \u201cA quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection.\u201d J Immunol. 2007 Jun 15;178(12):7890-901.<\/li>\n<\/ol>\n\n\n\n
    \n\n\n\n

    Originally posted on: https:\/\/immunaware.com\/technology\/pmhc-stability\/<\/a><\/p>\n\n\n\n

    Caltag Medsystems\u00a0<\/a>is the distributor of\u00a0immunAware\u00a0<\/a>products in the UK and Ireland. If you have any questions about these products, please\u00a0contact<\/a>\u00a0us<\/a>.<\/p>\n\n\n\n

    <\/p>\n","protected":false},"excerpt":{"rendered":"

    immunAware’s stability assay measures dissociation of pMHC complexes at 37\u00b0C. Distinguish between peptides that support formation of stable or unstable pMHC complexes.<\/p>\n","protected":false},"author":13,"featured_media":12234,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17,29,637,15],"tags":[1035,50,802,685],"class_list":["post-12206","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-flow-cytometry","category-immunology","category-t-cells","category-tetramer","tag-immunaware","tag-immunology","tag-mhc-tetramers","tag-t-cells-2"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=12206"}],"version-history":[{"count":5,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12206\/revisions"}],"predecessor-version":[{"id":12260,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12206\/revisions\/12260"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/12234"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=12206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=12206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=12206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}